Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) – Form 4 insider filing dated 26 June 2025
Director David W. J. McGirr reported the receipt of two new equity grants on 24 June 2025:
- 7,037 non-qualified stock options with an exercise price of $63.66, expiring 23 June 2035. The options vest in full on the earlier of 24 June 2026 or the day before the company’s 2026 annual shareholder meeting, subject to continued board service.
- 4,712 restricted stock units (RSUs), each convertible into one share of common stock, subject to the same vesting schedule as the options. RSUs have no expiration date.
Both transactions were coded “A” (acquired) and were reported as direct holdings. No shares were sold or otherwise disposed of, and no Rule 10b5-1 trading plan was indicated.
Following the grants, McGirr’s directly held derivative interests consist of 7,037 options and 4,712 RSUs. The filing does not disclose his current ownership of fully vested common shares, and there were no cash proceeds to the insider or the company at grant.
Investment view: The activity reflects routine annual director compensation. While insider equity awards can strengthen alignment between directors and shareholders, the aggregate 11,749 potential shares represent an immaterial fraction of Rhythm’s outstanding share count and pose only minimal future dilution. The absence of open-market purchases means there is no immediate demand signal for the stock.
Form 4 Overview – Rhythm Pharmaceuticals, Inc. (RYTM)
On 23 June 2025, Rhythm Pharmaceuticals filed a Form 4 disclosing that director Edward T. Mathers acquired common shares through the conversion of vested restricted stock units (RSUs).
- Transaction date: 18 June 2025
- Transaction code: M (exercise/settlement of derivative security)
- Securities acquired: 4,000 shares of common stock, delivered against 4,000 fully-vested RSUs
- Exercise price: $0 (RSU settlement, no cash paid)
Following the settlement, Mathers’ beneficial ownership is reported as 7,000 shares held directly and 5,771 shares held indirectly through the Edward Timothy Mathers Revocable Trust. The filing notes that the reporting person disclaims beneficial ownership of any trust-held shares in which he has no pecuniary interest.
No open-market purchases or sales were executed; the filing solely reflects an equity award vesting. All RSUs reported in Table II have now been converted and zero derivative securities remain outstanding under this specific grant.
For investors, the key takeaway is that a board member’s direct equity stake increased, albeit through a scheduled award rather than discretionary buying. While this does not inject fresh capital into the company, it modestly aligns the director’s incentives with shareholders and removes an overhang of unvested awards.
Rhythm Pharmaceuticals (RYTM) – Form 4 insider activity
On 06/18/2025, director Christophe Jean converted 4,000 fully-vested restricted stock units (RSUs) into an equal number of common shares (transaction code M). The RSUs carried a $0.00 exercise price and represented a one-for-one right to common stock.
Following the conversion, Jean directly owns 7,000 Rhythm shares and no remaining RSUs, according to the filing. No sales were disclosed.
The filing documents a modest increase in board-level ownership without any market sale, offering a limited but positive alignment signal for shareholders.
Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider transaction filed 06/23/2025
Director Jennifer L. Good reported the conversion of 4,000 restricted stock units (RSUs) into an equal number of common shares on 06/18/2025. The transaction is coded “M,” indicating a routine, compensation-related conversion with no cash exercise price ($0.00). Following the settlement, Good’s direct beneficial ownership increased to 7,000 common shares.
The filing notes that each RSU represented a contingent right to one share of common stock and fully vested on the same date; the units carry no expiration. No open-market purchase or sale occurred, and no derivative securities remain outstanding for the reporting person after the conversion.
Because the transaction reflects standard equity-based compensation for a director and involves a relatively small share count, it is unlikely to have a material impact on RYTM’s share float or governance structure. Investors typically view such conversions as neutral routine events rather than directional insider signals.
Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider filing dated 06/23/2025
Director David W. J. McGirr reported the vesting and settlement of 4,000 Restricted Stock Units (RSUs) on June 18, 2025 (Transaction Code M). Each RSU converted into one share of common stock at an exercise price of $0.00, resulting in the direct acquisition of 4,000 shares. Following the transaction, McGirr’s direct beneficial ownership in Rhythm Pharmaceuticals increased to 7,000 common shares. The filing shows no open-market purchase or sale and leaves McGirr with no remaining derivative securities tied to this award.
The RSUs fully vested on the same date and carry no expiration. Because the transaction reflects routine equity compensation rather than discretionary share purchases or sales, the economic impact on Rhythm Pharmaceuticals is limited, but it modestly aligns the director’s incentives with shareholder interests.
Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider filing
Director Lynn A. Tetrault reported the vesting and automatic conversion of 4,000 restricted stock units (RSUs) into an equal number of common shares on 18 Jun 2025 (transaction code M). No shares were sold, transferred, or otherwise disposed of, and the transaction was completed at a conversion price of $0.00, as RSUs carry no cash exercise cost.
Following the transaction, Tetrault’s direct beneficial ownership increased to 7,000 common shares. The RSUs had fully vested on the same date and do not carry an expiration date, indicating they were part of a previously granted equity incentive award. The filing contains no open-market purchases, option exercises for cash, or sales, and therefore does not create immediate cash proceeds for the insider or raise additional capital for the company.
Investor takeaway: The director’s decision to retain the newly issued shares rather than sell them marginally aligns insider interests with shareholders but is routine for RSU vesting events and is not large enough to materially affect share count or signal a strong directional view on RYTM’s valuation.